Stryker Corporation ($SYK) Stock Forecast: Down 2.8% Today

What is Stryker Corporation?

Stryker Corporation (SYK) is a medical technology company currently facing a notable downturn in the stock market.

Why is Stryker Corporation going down?

SYK stock is down 2.8% on May 27, 2026 16:10

• Stryker's stocks have fallen by 10% since March following a weak Q1 performance, partly due to a cybersecurity incident, contributing to the bearish market trend.
• There has been a proposed sale of 310,000 shares by a filer through an estate division, potentially intensifying the selling pressure and impacting the downward trajectory.
• Despite the decline in stock price, Stryker is maintaining its projections for organic sales growth for the full year and is expanding its product offerings, which may attract future investor interest.
• Goldman Sachs has adjusted Stryker's price target to $363 from $361, with a consistent Neutral rating, indicating a slight shift in valuation perspective that could have influenced the bearish sentiment.

SYK Price Chart

SYK Technical Analysis

SYK News

Stryker: Reaching Interesting Levels (NYSE:SYK)

Stryker's shares have dropped 10% since March due to a soft Q1 performance, attributed to a cybersecurity incident. Despite this, the company maintains its full-year guidance for 8.0-9.5% organic sales growth and is expanding its cardiovascular portfolio with the acquisition of Amplitude Vascular Systems. This price dip and maintained guidance make the current valuation of 20-21x earnings more attractive.

https://seekingalpha.com/article/4909174-stryker-reaching-interesting-levels

[144] STRYKER CORP SEC Filing

This article reports on a Form 144 SEC filing by Stryker Corp (SYK), detailing a proposed sale of common stock. The filing indicates a sale of 310,000 shares with an aggregate market value of $97,030,000, acquired on May 1, 1974, through an estate division. The document also includes information about the filer, issuer, and securities involved in the transaction.

https://www.stocktitan.net/sec-filings/SYK/144-stryker-corp-sec-filing-862643cefe1f.html

King Luther Capital Management Corp Has $169.15 Million Stock Holdings in Stryker Corporation $SYK

King Luther Capital Management Corp increased its stake in Stryker Corporation (NYSE:SYK) by 4.2% in the fourth quarter, bringing its total holdings to 481,259 shares valued at $169.15 million. Other institutional investors also adjusted their positions in Stryker, with the company currently holding a "Moderate Buy" consensus rating from analysts. The medical technology company recently announced a quarterly dividend and reported its latest earnings, missing analyst estimates but showing year-over-year revenue growth.

https://www.marketbeat.com/instant-alerts/filing-king-luther-capital-management-corp-has-16915-million-stock-holdings-in-stryker-corporation-syk-2026-05-27/

Goldman Sachs Adjusts Price Target on Stryker to $363 From $361, Maintains Neutral Rating

Goldman Sachs has updated its price target for Stryker (SYK) to $363, an increase from its previous target of $361. The firm has decided to maintain a Neutral rating on the medical technology company's stock. This adjustment reflects a minor change in Goldman Sachs' valuation perspective for Stryker.

https://www.marketscreener.com/news/goldman-sachs-adjusts-price-target-on-stryker-to-363-from-361-maintains-neutral-rating-ce7f5ad2d08afe23

A Look At Avanos Medical (AVNS) Valuation After Its Recent Share Price Surge

Avanos Medical (AVNS) has seen a significant share price surge of 72.35% in the past three months and 121.38% year-to-date, contrasting with more modest long-term returns. Despite reporting a loss of US$74.4 million, the stock trades at a Price-to-Sales (P/S) ratio of 1.6x, which is lower than the industry average but above its estimated fair P/S of 1.2x. This suggests the market is valuing Avanos Medical at a discount to sector benchmarks, though still at a premium to its fair value model, amidst strong recent momentum.

https://simplywall.st/stocks/us/healthcare/nyse-avns/avanos-medical/news/a-look-at-avanos-medical-avns-valuation-after-its-recent-sha

Trending Today

Stryker Corporation Price History

01.04.2026 - SYK Stock was down 5.4%

• A recent cyberattack on Stryker Corporation has impacted the company's growth, resulting in stalled shipments and a growth rate of 2.6%. This incident has sparked concerns among investors regarding the company's cybersecurity measures and operational resilience.
• Stryker's participation in the Bank of America Securities 2026 Global Healthcare Conference demonstrates the company's commitment to addressing concerns and presenting its growth strategies to investors and stakeholders.
• BTIG has lowered Stryker's stock price target to $379 from $397 due to the cybersecurity breach and below-expectation Q1 2026 results. This revision indicates that investors are reassessing their expectations for Stryker's stock in light of the challenges faced by the company.

01.04.2026 - SYK Stock was down 5.0%

• The decline in Stryker's stock price could be linked to a price target reduction by BTIG. This revision followed a cybersecurity incident affecting operations and order fulfillment, leading to lower-than-expected first-quarter results.
• The positive earnings announcement from Zimmer Biomet Holdings, Inc. and optimistic forecasts for its 2026 earnings potential may have indirectly influenced investor focus, potentially impacting Stryker's stock performance.
• Boston Scientific's robust Q1 2026 results and active merger and acquisition activities might have highlighted growth prospects in the healthcare sector, temporarily diverting attention and investments from Stryker.
• Reports of Conestoga Capital Advisors LLC offloading shares of Mercury Systems Inc. could have also contributed to market sentiment shifts. This could have led investors to readjust their allocations within the healthcare and technology sectors, potentially affecting Stryker's stock adversely.

04.01.2026 - SYK Stock was up 0.3%

• The bullish movement in SYK stock can be attributed to the company's announcement of a 4.8% increase in its quarterly dividend, showcasing financial strength and investor confidence.
• Institutional bullish sentiment towards the stock is evident with Jones Financial Companies Lllp increasing its stake in Stryker Corporation by 20.8% despite insider selling.
• Stryker's strong quarterly earnings, beating expectations with an 11.4% year-over-year revenue increase, have likely contributed to the positive market movement.
• Overall, the market seems to be reacting positively to Stryker's robust financial performance and strategic decisions, setting a bullish tone for the stock's future outlook.

06.00.2026 - SYK Stock was up 5.1%

• Stryker's bullish movement today could be attributed to multiple factors:
• The appointment of Scott Sacha as Vice President of Enterprise Data Services, signaling the company's commitment to enhancing data-driven strategies for improving patient outcomes globally.
• The initiation of coverage by Raymond James with a 'buy' rating and a target price of $418, indicating positive sentiment and potential growth prospects for the company.
• The acquisition of Stryker's spine implant manufacturing facility by VB Spine LLC, expanding global manufacturing capabilities and strategic footprint, seen as a positive move for Stryker's overall business outlook.
• Overall, these developments highlight Stryker's efforts to strengthen its position in the medical technology industry through strategic partnerships, data-driven initiatives, and favorable analyst ratings, contributing to the bullish market movement of the stock today.

27.04.2026 - SYK Stock was down 2.8%

• Stryker's stocks have fallen by 10% since March following a weak Q1 performance, partly due to a cybersecurity incident, contributing to the bearish market trend.
• There has been a proposed sale of 310,000 shares by a filer through an estate division, potentially intensifying the selling pressure and impacting the downward trajectory.
• Despite the decline in stock price, Stryker is maintaining its projections for organic sales growth for the full year and is expanding its product offerings, which may attract future investor interest.
• Goldman Sachs has adjusted Stryker's price target to $363 from $361, with a consistent Neutral rating, indicating a slight shift in valuation perspective that could have influenced the bearish sentiment.

30.00.2026 - SYK Stock was up 2.8%

• Stryker (SYK) experienced a strong bullish movement today following a series of positive events and analyst actions.
• Resmed's strong Q2 results and increased CPAP demand in the healthcare sector likely boosted investor confidence in medical device companies, including Stryker.
• Analyst upgrades from Needham, Canaccord Genuity, and BTIG, along with institutional investments from Mirae Asset Global Investments Co. Ltd., contributed to the positive sentiment surrounding Stryker's stock.
• The market's reaction indicates that investors are optimistic about Stryker's future growth prospects, solid financial performance, and continued innovation in the medical technology space.

08.11.2025 - SYK Stock was down 1.7%

• The bearish movement in SYK's stock today could be attributed to the significant insider selling observed recently, with insiders offloading a substantial number of shares worth millions of dollars. This selling pressure might have raised concerns among investors about the company's future performance.
• Despite the insider selling, institutional investors like Natixis have shown confidence in Stryker by increasing their stake, indicating a positive outlook for the company.
• The recent promotion of a new president and COO to lead the M&A strategy could signal potential changes in the company's direction, which might have caused uncertainty among investors and contributed to the bearish market movement.
• While Stryker has been making strategic acquisitions and reporting strong financial results, the mixed signals from insider selling and institutional buying could have created a sense of ambiguity in the market, leading to the bearish trend in SYK's stock today.

06.02.2026 - SYK Stock was down 1.9%

• Pitcairn Co. reducing its stake in Stryker Corporation by 30.8% and Director Ronda E. Stryker selling a significant number of shares might have signaled concerns among investors, leading to a bearish sentiment.
• Despite positive news such as surpassing EPS expectations, revenue growth, and a quarterly dividend declaration, the significant sell-off by key stakeholders could have outweighed these positive factors.
• The muted market reaction to William Blair's Outperform rating and the lack of a new price target may have also contributed to the bearish movement as investors may have been expecting a more bullish outlook.
• The increase in stake by Dimensional Fund Advisors LP and other institutional investors contrasts with the significant insider selling, creating uncertainty and potentially adding to the downward pressure on the stock price.

11.02.2026 - SYK Stock was down 5.2%

• Stryker Corporation faced a severe cyber attack allegedly orchestrated by the Iranian-linked hacker group Handala, resulting in a global system outage and the disruption of operations at its Cork headquarters.
• The attack, suspected to involve wiper malware that permanently deletes data, has left thousands of employees stranded and raised concerns about the potential impact on global medical device production and supply chains.
• This cybersecurity breach not only poses immediate operational challenges for Stryker but also highlights the growing threats faced by companies in the healthcare sector, emphasizing the critical importance of robust cybersecurity measures in safeguarding sensitive data and maintaining business continuity.

11.02.2026 - SYK Stock was down 4.3%

• Factors contributing to the significant downward movement in Stryker Corporation's stock today include:
• Adjustments in positions by institutional investors such as Kepler Cheuvreux Suisse SA and Mackenzie Financial Corp, involving the acquisition or sale of substantial shares.
• Director Ronda E. Stryker's sale of 250,000 shares for $90.73 million, potentially signaling internal concerns or profit-taking and impacting investor confidence.
• Despite impressive quarterly earnings and revenue growth by Stryker, the bearish trend may reflect broader market uncertainties or profit-taking following recent positive results.
• The overall news of a thriving Bio-Implants Market and industry competition, featuring key players like Boston Scientific and Zimmer Biomet, could have also influenced the negative pressure on Stryker's stock.